NanoViricides Inc. (NNVC)

[changes_iv]

The non-GLP study conducted by KARD Scientific, Inc. Dr. Krishna Menon, President of KARD and consulting Regulatory Officer for NanoViricides, Inc., advised NanoViricides, Inc. that some of the orally administered drug candidates provided by NanoViricides showed efficacy in combatting highly lethal influenza H1N1 infection in mice. Are you aware of any GLP toxicology studies that contradict KARD Scientific, Inc. non-GLP findings?

Wednesday, 12/10/14 --- Those that proposed that the Doctor's recent purchase of 50,000 shares stood as a symbol of his confidence in the company now need to consider what his sale of a multiple of that amount might mean. Seriously, I think his recent purchase was meant to mitigate against any questions that these sales might raise. ~ loanranger

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108956514

Care to revise and extend your remarks based on Dr. Milton Boniuk's most recent STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
http://ih.advfn.com/p.php?pid=nmona&article=67659713
http://ih.advfn.com/p.php?pid=nmona&article=67464536